[Salvage radiotherapy after prostatectomy - what do do in case of elevated post operative PSA or macroscopic relapse?]
- PMID: 34702645
- DOI: 10.1016/j.canrad.2021.08.017
[Salvage radiotherapy after prostatectomy - what do do in case of elevated post operative PSA or macroscopic relapse?]
Erratum in
-
[Erratum to "Salvage radiotherapy after prostatectomy - what do in case of elevated postoperative PSA or macroscopic relapse?" [Cancer Radiother. 25 (2021) 822-9]].Cancer Radiother. 2022 Feb-Apr;26(1-2):424. doi: 10.1016/j.canrad.2021.12.001. Epub 2022 Jan 14. Cancer Radiother. 2022. PMID: 35039241 French. No abstract available.
Abstract
The management of the postoperative biological relapse of prostate cancer is most often based on salvage radiotherapy (RT) and a variable duration of hormone therapy (HT) in addition. The indications for RT±HT become more consensual for the adjuvant postoperative situation or in the event of a rising PSA level after a period where an undetectable PSA level was achieved. On the other hand, in the event of detectable PSA immediately postoperatively or in the event of a biological recurrence with macroscopic relapse in the prostate bed seen on conventional imaging assessment, the treatment options are still being evaluated. This article will describe these 2 situations and their current management but also will come through assessments with the contribution of modern imaging and new treatment options in terms of RT dose and RT±HT combination.
Keywords: Cancer de la prostate; Clinical trials; Detectable PSA; Essais cliniques; Macroscopic relapse; PSA détectable; Prostate cancer; Radiothérapie de rattrapage; Rechute macroscopique; Salvage radiation therapy.
Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous